Vivoryon Therapeutics AG (GB:0R3M) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vivoryon Therapeutics N.V. has announced promising new data showing that its drug varoglutamstat significantly improves kidney function in diabetic patients. In addition to kidney benefits, the treatment also exhibited potential health improvements including weight loss and lower blood pressure without notable adverse events. The company is now planning to advance the drug into a Phase 2 clinical study for diabetic kidney disease.
For further insights into GB:0R3M stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue